International Journal of Clinical Oncology最新文献

{"title":"Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.","authors":"Ryosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, Hiroki Yukami, Hiroyuki Uetake, Masahiro Tsuda, Takeshi Suto, Naotoshi Sugimoto, Hitoshi Ojima, Yasumasa Takii, Hisateru Yasui, Masato Komoda, Yasuhiro Shimada, Akihito Tsuji, Toshifumi Yamaguchi, Ryoichi Sawada, Katsunori Shinozaki, Satoshi Otsu, Kunitoshi Shigeyasu, Kenji Tsuchihashi, Takao Tamura, Manabu Shiozawa, Hideki Ueno, Tadamichi Denda, Takahiko Ito, Atsuo Takashima","doi":"10.1007/s10147-026-02999-z","DOIUrl":"10.1007/s10147-026-02999-z","url":null,"abstract":"<p><strong>Background: </strong>For patients with left-sided metastatic colorectal cancer (mCRC), the recommended first-line treatment is anti-epidermal growth factor receptor (anti-EGFR) antibodies, such as cetuximab or panitumumab, plus doublet chemotherapy. However, the differences in outcomes between cetuximab and panitumumab remain unknown.</p><p><strong>Methods: </strong>Clinical data of patients with left-sided all RAS or KRAS wild-type mCRC who received cetuximab or panitumumab plus doublet chemotherapy were retrospectively collected from 24 institutions in Japan. The patients were divided into two groups: the cetuximab and panitumumab groups. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were compared between the two groups.</p><p><strong>Results: </strong>A total of 233 patients were enrolled: 87 (37.3%) in the cetuximab group and 146 (62.7%) in the panitumumab group. Median OS, PFS, and RR of the cetuximab and panitumumab groups were 26.6 months (95% confidence interval [CI], 19.7-33.4) versus 31.8 months (95% CI, 25.7-37.9), 9.7 months (95% CI, 6.9-12.5) versus 12.4 months (11.1-13.7), and 57.8% versus 71.0%, respectively. In multivariate analysis, OS and RR were significantly better in the panitumumab group than in the cetuximab group (adjusted hazard ratio 0.69, 95% CI 0.50-0.99, p = 0.04; adjusted odds ratio 2.00, 95% CI 1.07-3.73, p = 0.03) and PFS was similar between the two groups (adjusted hazard ratio 0.75, 95% CI 0.55-1.01, p = 0.05).</p><p><strong>Conclusion: </strong>As a first-line treatment for patients with left-sided all RAS or KRAS wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"851-858"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A paradigm shift in genetic predisposition to colorectal cancer: the impact of germline multigene panel testing on diagnosis and management.","authors":"Kenji Fujiyoshi, Tomoya Sudo, Satoshi Shimamura, Rie Sugihara, Kahori Hisada, Kenta Takaki, Masayuki Takamatsu, Maako Kikuchi, Fumiki Koga, Takahiro Shigaki, Naohiro Yoshida, Takafumi Ohchi, Yuichi Goto, Takefumi Yoshida, Taro Isobe, Naoki Mori, Hisamune Sakai, Toru Hisaka, Fumihiko Fujita","doi":"10.1007/s10147-026-03003-4","DOIUrl":"10.1007/s10147-026-03003-4","url":null,"abstract":"<p><p>Hereditary colorectal cancer (HCRC), arising from pathogenic germline variants, accounts for 5-10% of all CRCs. The widespread clinical adoption of next-generation sequencing (NGS) and multigene panel testing (MGPT) has fundamentally transformed the diagnostic paradigm for this genetic predisposition. This review summarizes the latest epidemiological data on genetic predisposition to CRC and examines the essential practical changes required for genomics-based precision medicine. Recent large-scale genomic cohort studies have consistently revealed a higher prevalence of pathogenic/likely pathogenic germline variants (PGVs) in unselected CRC populations than previously recognized, ranging from 3.3 to 15.5%. This proportion is dramatically elevated in patients with early onset CRC (EOCRC), defined as a diagnosis before age 50, where prevalence consistently exceeds 15%. Notably, MGPT has expanded the etiological spectrum far beyond Lynch syndrome (LS)-related genes, demonstrating a significant contribution from non-LS and high- and moderate-penetrance genes, particularly those associated with homologous recombination deficiency (HRD). Consequently, the management of genetic predisposition to CRC is rapidly shifting from single syndrome-based diagnoses to individualized precision medicine guided by gene-specific lifetime cancer risks. To realize clinical benefits, two imperatives must be addressed: (1) the implementation of universal genomic screening for all patients with EOCRC and (2) the development of proactive medical-contact approach models in cascade screening for at-risk relatives. Nevertheless, the viability of this proposal varies considerably between Europe, America, and Asia. Considerable uncertainty surrounds implementation in Asia, where a plethora of challenges must be overcome to facilitate the integration of genomic medicine within the Asian context.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"812-822"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147466513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the 9th Edition of the UICC TNM classification and the prognostic impact of nodal spread in salivary gland cancer.","authors":"Satoshi Kano, Takayoshi Suzuki, Nayuta Tsushima, Hiroshi Idogawa, Masaki Kakumu, Hayato Imanari, Akihiro Homma","doi":"10.1007/s10147-026-02980-w","DOIUrl":"10.1007/s10147-026-02980-w","url":null,"abstract":"<p><strong>Background: </strong>The 9th edition of the UICC TNM classification redefined N categories and clinical stages for salivary gland cancer (SGC). We validated the prognostic utility of this redefinition and evaluated the impact of anatomical nodal spread.</p><p><strong>Methods: </strong>We retrospectively analyzed 166 patients with SGC and 93 parotid gland cancer (PGC) patients treated with curative surgery. Cases were restaged according to the TNM classification of the UICC 9th edition. Kaplan-Meier survival curves, Cox models, and statistical indices (AIC, likelihood ratio χ², C-index) were used to compare the findings based on the 8th and 9th editions. Nodal metastases were classified as \"Intraparotid lymph nodes (LNs) only\", \"Limited to levels I-III LNs\", and \"Beyond levels I-III LNs\".</p><p><strong>Results: </strong>Kaplan-Meier curves showed clearer separation by N category and clinical stage for the 9th edition, although its prognostic performance by statistical indices was similar to that of the 8th edition. In the PGC surgery subset, LN metastasis, particularly N2 in the 9th edition, was the strongest adverse prognostic factor, and the new 9th edition pathological N categories were also useful. Additionally, prognosis worsened with increasing nodal extent. Twelve patients with metastases beyond levels I-III developed distant metastases despite standard treatment, and 10 with salivary duct carcinoma, indicating potential benefit from adjuvant systemic therapy.</p><p><strong>Conclusions: </strong>Kaplan-Meier analyses suggested that the 9th edition provided better intercategory discrimination than the 8th edition, despite no statistical superiority being demonstrated. Nodal metastasis extending beyond levels I-III may be a useful biomarker for selecting patients for adjuvant systemic therapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"823-833"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence for diagnosis and triage in oral cancer: a clinician‑centered narrative review.","authors":"Shin-Ichiro Hiraoka, Kohei Kawamura, Ryo Akiyama, Yutaka Itakura, Susumu Tanaka, Narikazu Uzawa","doi":"10.1007/s10147-026-03002-5","DOIUrl":"10.1007/s10147-026-03002-5","url":null,"abstract":"<p><strong>Background: </strong>Early diagnosis of oral squamous cell carcinoma (OSCC) remains challenging, with survival largely stage-dependent at presentation. Artificial intelligence (AI) promises to enhance detection and clinical decision-making across clinical photographs, radiology, optical imaging, and digital pathology.</p><p><strong>Methods: </strong>This narrative review synthesizes peer-reviewed PubMed-indexed English-language studies up to October 2025, prioritizing prospective designs, external validation, and clinically interpretable models. We focus on tasks relevant to clinicians: lesion triage from clinical images, prediction of nodal metastasis on CT/MRI/PET, margin assessment with optical modalities, and histopathology-based diagnosis/grading. We also discuss implementation issues: dataset shift, bias, and reporting standards.</p><p><strong>Results: </strong>In clinical photographs, deep learning achieves high diagnostic accuracy for OSCC and oral potentially malignant disorders (OPMD) classification in single-center studies and shows promising generalization with multi-site external testing, yet performance still degrades on out-of-distribution images and under real-world artifacts. In radiology, radiomics and deep learning models improve risk stratification and prediction of cervical nodal metastasis beyond conventional imaging, particularly with multimodal feature fusion. Optical methods such as hyperspectral spatial frequency domain imaging and OCT combined with AI show feasibility for intraoperative margin assessment and in-clinic triage. Digital pathology models on whole-slide images approach expert-level classification for OSCC diagnosis and are beginning to predict malignant transformation risk in oral epithelial dysplasia; however, rigorous prospective validation remains scarce.</p><p><strong>Conclusion: </strong>AI systems for OSCC are maturing and clinically oriented. Before routine adoption, studies must demonstrate external validity, clinician-in-the-loop performance, calibration, and impact on time-to-diagnosis and patient outcomes. Pragmatic trials and transparent reporting are essential to move beyond proof-of-concept into equitable clinical benefit.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"794-803"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term follow-up of neoadjuvant chemotherapy in resectable human papillomavirus-associated oropharyngeal cancer.","authors":"Ryo Kawaura, Tomoya Yokota, Kunihiro Fushiki, Satoshi Hamauchi, Yusuke Onozawa, Kayo Sakamoto, Nobuyuki Sakuma, Takashi Kojima, Shinya Morita, Takashi Mukaigawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tetsuro Onitsuka","doi":"10.1007/s10147-026-03004-3","DOIUrl":"10.1007/s10147-026-03004-3","url":null,"abstract":"<p><strong>Background: </strong>De-escalation strategies have gained increasing attention for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). We previously introduced an approach using upfront neoadjuvant chemotherapy (NAC) to facilitate less invasive surgery and potentially omit postoperative radiotherapy (PORT) or chemoradiotherapy (POCRT). This study evaluated the long-term outcomes and late toxicities of NAC followed by surgery after a 5-year follow-up.</p><p><strong>Methods: </strong>We retrospectively analyzed 41 patients with resectable HPV-positive OPSCC who received NAC followed by primary tumor resection, with or without neck dissection. Patients were treated with triplet NAC comprising either docetaxel, cisplatin, and 5-fluorouracil (TPF) or carboplatin, paclitaxel, and cetuximab.</p><p><strong>Results: </strong>A pathological complete response (pCR) at both the primary site and lymph nodes was achieved in 25 patients (61.0%), and PORT/POCRT was required in 6 patients (14.6%). Among the 36 patients who received NAC-TPF, the number of TPF cycles administered in the pCR group was significantly higher than in the non-pCR group (p = 0.0401). The median follow-up period was 5.3 years, with 5-year overall and progression-free survival rates of 92.4% and 80.1%, respectively. Recurrence occurred in 25% of the non-pCR group and 8% of the pCR group. All patients resumed oral intake without nutritional intervention within 35 days after treatment, and no severe late toxicities impairing daily life were observed.</p><p><strong>Conclusion: </strong>Long-term follow-up demonstrated that NAC followed by surgery-aimed at achieving less invasive procedures and avoiding PORT/POCRT-is feasible and promising in terms of survival and late toxicities in patients with resectable HPV-associated OPSCC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"859-867"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited reliability of H3K27M detection using a commercially available blood-based comprehensive genomic profiling test in patients with diffuse midline gliomas: analysis of the nationwide C-CAT database in Japan.","authors":"Yuzo Hasegawa, Toshihiko Iuchi, Junji Hosono, Taiki Setoguchi, Sana Yokoi, Tsukasa Sakaida","doi":"10.1007/s10147-026-03009-y","DOIUrl":"10.1007/s10147-026-03009-y","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess the ability of FoundationOne Liquid CDx (F1 Liquid), a blood-based comprehensive genomic profiling test introduced in Japan in 2021, to detect the H3K27M mutation in patients with diffuse midline glioma using a nationwide real-world database in Japan.</p><p><strong>Methods: </strong>We identified patients with IDH-wildtype diffuse gliomas in midline locations registered in the Center for Cancer Genomics and Advanced Therapeutics database from June 2019 to April 2024. Detection rates of the H3K27M mutation and other major variants were compared across two blood-based comprehensive genomic profiling tests, F1 Liquid and Guardant360 CDx, and three tissue-based, FoundationOne CDx (F1 CDx), NCC Oncopanel, and GenMine TOP. Predictors of H3K27M mutation detection were analyzed using logistic regression.</p><p><strong>Results: </strong>We identified 114 patients with diffuse gliomas located in the midline. Among these, 31.6% underwent F1 Liquid testing, which had only a 2.8% detection rate for the H3K27M mutation. In contrast, F1 CDx testing had a significantly higher detection rate of 92.2% (p < 0.01). Not undergoing F1 Liquid testing was the only independent predictor of H3K27M detection (odds ratio, 267; 95% confidence interval, 44.4-5250; p < 0.01). F1 Liquid also showed low detection rates for TP53 (2.8%), PDGFRA (0%), and NF1 (2.8%).</p><p><strong>Conclusion: </strong>Our findings indicate a critical limitation of F1 Liquid in detecting the H3K27M and other significant mutations in diffuse midline glioma.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"899-905"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and prospects of computer-assisted surgery (CAS) in oral and maxillofacial reconstruction.","authors":"Yoshihiro Morita, Narikazu Uzawa","doi":"10.1007/s10147-025-02896-x","DOIUrl":"10.1007/s10147-025-02896-x","url":null,"abstract":"<p><p>Computer-assisted surgery (CAS) has emerged as a transformative approach for oral and maxillofacial reconstruction, significantly enhancing surgical precision, efficiency, and patient outcomes. This review outlines the current status and future prospects of CAS, with a focus on its application in mandibular and maxillary reconstruction. CAS encompasses technologies such as virtual surgical planning (VSP), computer-aided design and manufacturing (CAD/CAM), and patient-specific plates (PSPs), which have become integral to procedures such as implant placement, orthognathic surgery, and fracture management. While Western countries have led the adoption of CAS, its implementation in Asia, including Japan, is steadily progressing and supported by innovations such as the domestically developed CAS system. Despite its advantages, CAS faces challenges, such as high costs, long preparation times, and limited intraoperative flexibility. This review highlights the clinical benefits, technological advancements, and regional developments in CAS, emphasizing the need for standardized evaluation methods, cost-effective solutions, and broader clinical integration to ensure sustainable and equitable access to advanced surgical care.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"804-811"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).","authors":"Taro Shibuki, Riu Yamashita, Tadayoshi Hashimoto, Takao Fujisawa, Mitsuho Imai, Junichiro Yuda, Takeshi Kuwata, Toshihiro Misumi, Yoshiaki Nakamura, Hideaki Bando, Kaname Kojima, Sayuri Tokioka, Ippei Chiba, Naoki Nakaya, Atsushi Hozawa, Seizo Koshiba, Nobuo Fuse, Sakae Saito, Ritsuko Shimizu, Woong-Yang Park, Kengo Kinoshita, Takayuki Yoshino","doi":"10.1007/s10147-026-03001-6","DOIUrl":"10.1007/s10147-026-03001-6","url":null,"abstract":"<p><strong>Background: </strong>Early detection of cancer and precise recurrence monitoring remain major unmet needs in oncology. Conventional screening is limited to a few cancer types, leaving nearly half of cancers without established programs. Multi-cancer early detection (MCED) tests based on circulating tumor biomarkers have shown promise, but sensitivity for early-stage remains a challenge. In parallel, detection of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) has emerged as a powerful prognostic and predictive tool, though current assays remain limited in sensitivity and specificity. This study aims to integrate multi-omics data to develop more refined and highly sensitive MCED and MRD assays.</p><p><strong>Methods: </strong>This study leverages clinical information and biospecimens from patients with cancer and cancer-naïve individuals. Samples from patients with cancers will be derived from the MONSTAR-SCREEN-3 study, while those from cancer-naïve individuals will be obtained from the Tohoku Medical Megabank Project. Comprehensive analyses will include whole-genome sequencing (WGS), whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), proteomics, metabolomics, and microbiome profiling using stool and saliva. Artificial intelligence (AI)-based multi-omics integration will be performed to develop novel MCED and MRD assays and to evaluate their clinical performance. The primary endpoints are the sensitivity and specificity of MCED and MRD assays.</p><p><strong>Discussion: </strong>This is the first large-scale study to integrate comprehensive multi-omics profiling with AI for MCED and MRD assay development. The findings are expected to advance precision oncology by improving early diagnosis and recurrence monitoring.</p><p><strong>Trial registration: </strong>UMIN000053815, approved by the Institutional Review Board of the National Cancer Center Hospital East.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"843-850"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of newly detected pharyngo-laryngeal lesions during transoral endoscopic surgery.","authors":"Satoru Miyamaru, Daizo Murakami, Hidenori Katsura, Hideaki Miyamoto, Kenshi Matsuno, Sadahiro Yamamura, Narumi Hayashi, Toshinori Hirai, Yasuhito Tanaka, Yorihisa Orita","doi":"10.1007/s10147-026-03013-2","DOIUrl":"10.1007/s10147-026-03013-2","url":null,"abstract":"<p><strong>Background: </strong>Advances in image-enhanced endoscopy have improved early detection of superficial squamous cell carcinomas in the oropharynx, hypopharynx, and larynx. As a minimally invasive treatment, transoral endoscopic surgery offers advantages over (chemo)radiotherapy and open surgery, including preservation of voice and swallowing function and the option of future radiotherapy. However, some lesions remain undetected during preoperative examinations of conscious patients and are identified only intraoperatively under general anesthesia. In this study, we sought to clarify the clinical characteristics of lesions newly detected during surgery.</p><p><strong>Methods: </strong>We retrospectively reviewed 193 patients with 284 superficial squamous cell carcinoma lesions of the oro-hypopharynx or larynx who underwent transoral endoscopic surgery between January 2016 and December 2024. To identify factors associated with intraoperative detection, newly identified lesions were compared with preoperatively detected lesions in terms of location, tumor size, histopathology, and preoperative endoscopic examination conditions.</p><p><strong>Results: </strong>Among the 284 lesions, 24 (8.5%) were newly detected intraoperatively, which were significantly smaller than those detected preoperatively (median: 7.5 vs. 17 mm) and were mainly located on the posterior walls of the oropharynx and hypopharynx. Sixteen lesions were identified using narrow-band imaging (NBI) alone, whereas eight required additional Lugol staining. Lesions requiring Lugol staining were significantly more likely to be carcinoma in situ than invasive carcinoma.</p><p><strong>Conclusions: </strong>Intraoperatively detected lesions were generally smaller and more frequently located on the posterior pharyngeal wall. Given the limitations of conscious endoscopic examinations, meticulous intraoperative inspection using NBI and Lugol staining is essential to avoid overlooking indistinct lesions.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"906-914"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-related prognostic trends in surgically resected female lymph node-metastatic gastric cancer: insights from SEER.","authors":"Bozhi Hu, Yinli Zhang, Yingjiang Ye, Zhidong Gao, Chao Wang","doi":"10.1007/s10147-026-03045-8","DOIUrl":"https://doi.org/10.1007/s10147-026-03045-8","url":null,"abstract":"<p><strong>Background: </strong>Understanding the relationship between age and prognosis of female lymph node-metastatic gastric cancer (FLMGC) remains limited. This study aimed to elucidate the prognostic impact of age on FLMGC.</p><p><strong>Methods: </strong>This population-based retrospective analysis used data from the SEER database. After applying the exclusion criteria, a final cohort of 1,172 FLMGC cases was included. The patients were categorized by age into five groups: ≤ 50 years (n = 144), 51-60 years (n = 192), 61-70 years (n = 291), 71-80 years (n = 325), and ≥ 81 years (n = 220). Cancer-specific survival (CSS) was selected as the outcome in this study.</p><p><strong>Results: </strong>Significant factors for CSS identified in multivariate analysis included age, tumor differentiation, AJCC T and N stages, systemic therapy, number of positive lymph nodes, and total number of retrieved lymph nodes. Age had a nonlinear effect on CSS (P for nonlinearity < 0.001), with the lowest risk occurring in the 55-60 year age group.</p><p><strong>Conclusions: </strong>This SEER-based study revealed a nonlinear relationship between age and FLMGC prognosis, with the lowest risk occurring in the 55-60-year age group.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}